Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors
Authors
Keywords
-
Journal
RHEUMATOLOGY
Volume 58, Issue Supplement_7, Pages vii59-vii67
Publisher
Oxford University Press (OUP)
Online
2019-07-08
DOI
10.1093/rheumatology/kez308
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients
- (2019) J. Rogado et al. EUROPEAN JOURNAL OF CANCER
- Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
- (2018) Noha Abdel-Wahab et al. ANNALS OF INTERNAL MEDICINE
- Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors
- (2018) Merav Lidar et al. AUTOIMMUNITY REVIEWS
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
- (2018) Frederick Arce Vargas et al. CANCER CELL
- A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
- (2018) Xuexiang Du et al. CELL RESEARCH
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
- (2018) Angeliki M. Stamatouli et al. DIABETES
- Early B cell changes predict autoimmunity following combination immune checkpoint blockade
- (2018) Rituparna Das et al. JOURNAL OF CLINICAL INVESTIGATION
- Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression
- (2018) Yanxia Guo et al. PLoS One
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen
- (2018) Laura C. Cappelli et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Immune Checkpoint Inhibitor Toxicity
- (2018) David J. Palmieri et al. Current Oncology Reports
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors
- (2018) Sabina Sandigursky et al. Current Rheumatology Reports
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
- (2018) Samantha L. Bucktrout et al. Genome Medicine
- Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
- (2018) Emma C. de Moel et al. Cancer Immunology Research
- Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma
- (2017) Bethsabée Garel et al. JOINT BONE SPINE
- Is autoimmunity the Achilles' heel of cancer immunotherapy?
- (2017) Carl H June et al. NATURE MEDICINE
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
- (2017) Jarushka Naidoo et al. ONCOLOGIST
- Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology
- (2017) Laura C. Cappelli et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Arthritis after cancer immunotherapy: symptom duration and treatment response
- (2017) Melanie H. Smith et al. ARTHRITIS CARE & RESEARCH
- Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
- (2017) Laura C. Cappelli et al. ARTHRITIS CARE & RESEARCH
- Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer
- (2017) Maria E. Suarez-Almazor et al. Arthritis & Rheumatology
- The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma
- (2016) B. Lee et al. ANNALS OF ONCOLOGY
- Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
- (2016) Laura C Cappelli et al. ANNALS OF THE RHEUMATIC DISEASES
- Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
- (2016) David Y. Oh et al. CANCER RESEARCH
- Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
- (2016) Michiel van der Vlist et al. Nature Reviews Rheumatology
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
- (2016) Katrin Klocke et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- (2016) Krista Dubin et al. Nature Communications
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies
- (2015) Steven Orlov et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways
- (2015) Cuiping Liu et al. ARTHRITIS RESEARCH & THERAPY
- Drug-Associated Dermatomyositis Following Ipilimumab Therapy
- (2015) Shirwa Sheik Ali et al. JAMA Dermatology
- CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
- (2014) L. Robert et al. CLINICAL CANCER RESEARCH
- Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4
- (2014) H. S. Kuehn et al. SCIENCE
- Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma
- (2014) Joshua S Manusow et al. Journal for ImmunoTherapy of Cancer
- CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients
- (2013) Jennifer Pieper et al. BMC IMMUNOLOGY
- The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
- (2013) Jérôme Galon et al. IMMUNITY
- Lymphocytic Vasculitis of the Uterus in a Patient With Melanoma Receiving Ipilimumab
- (2013) David R. Minor et al. JOURNAL OF CLINICAL ONCOLOGY
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy
- (2013) Myriam N. Bouchlaka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Drug-Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in Two Patients After Treatment With Ipilimumab, an Antagonist of CTLA-4
- (2013) Barbara L. Goldstein et al. Arthritis & Rheumatology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started